logo

Video encyclopedia

Semaglutide

3:37

What is Trulicity (Dulaglutide), how does it work, how do I use it?

2:51

Jeffrey Berger, MD: Deciding Between GLP1 Agonists or SGLT2 Inhibitors

1:35

Dr. Gobind Rai Garg discusses the topic - Amantadine

2:03

Nanome: Collaborative Structure-Based Drug Design in Virtual Reality

1:28

Dr. Paik on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

Semaglutide is a pharmaceutical drug developed by Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016.
Explore contextually related video stories in a new eye-catching way. Try Combster now!
  • Mechanism of action 

  • History